Vycor Medical (VYCO) Cash from Financing Activities (2010 - 2026)
Vycor Medical's (VYCO) quarterly Cash from Financing Activities came in at -$14910.0 in Q1 2026, up 15.72% year-on-year from -$12885.1 in Q1 2025, and little changed on a QoQ basis from -$14874.0 in Q4 2025.
Vycor Medical (VYCO) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Vycor Medical (VYCO) has 17 years of Cash from Financing Activities data on file, last reported at -$14910.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 15.72% year-over-year to -$14910.0 in Q1 2026; TTM through Mar 2026 was $1968.0, a 121.25% increase from a year earlier, with the FY2025 full-year figure at -$812.0, up 89.25% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$14910.0, roughly flat from -$14874.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for VYCO reached as high as $68409.0 in Q1 2022 and fell as low as -$17690.0 in Q1 2025.
- Historically, Cash from Financing Activities has averaged $8401.4 across 5 years, with a median of -$8819.0 in 2023.
- Across the five-year window, Cash from Financing Activities soared 293.33% in 2022 and tumbled 130.31% in 2023, its largest moves.
- Year by year, Cash from Financing Activities stood at $37497.0 in 2022, then sank by 130.31% to -$11367.0 in 2023, then dropped by 22.06% to -$13874.0 in 2024, then declined by 7.21% to -$14874.0 in 2025, then declined by 0.24% to -$14910.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$14910.0 in Q1 2026, -$14874.0 in Q4 2025, and $36957.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Vycor Medical | 2.34 Mn | 2.16 Mn | 375,153.00 | -14,910.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,910.00 |
| Mar 31, 2026 | -14,910.00 |
| Dec 31, 2025 | -14,874.00 |
| Dec 31, 2025 | -14,874.00 |
| Sep 30, 2025 | 36,957.00 |
| Sep 30, 2025 | 36,957.00 |
| Jun 30, 2025 | -5,205.00 |
| Jun 30, 2025 | -5,205.00 |
| Mar 31, 2025 | -17,690.00 |
| Mar 31, 2025 | -17,690.00 |
| Dec 31, 2024 | -13,874.00 |
| Dec 31, 2024 | -13,874.00 |
| Sep 30, 2024 | 32,898.00 |
| Sep 30, 2024 | 32,898.00 |
| Jun 30, 2024 | -10,595.00 |
| Jun 30, 2024 | -10,595.00 |
| Mar 31, 2024 | -15,983.00 |
| Mar 31, 2024 | -15,983.00 |
| Dec 31, 2023 | -11,367.00 |
| Dec 31, 2023 | -11,367.00 |